Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 12/20 | 0.64 |
| ▸ | CCND1 | P24385 | 11/20 | 0.64 |
| ▸ | CCND2 | P30279 | 11/20 | 0.64 |
| ▸ | CCND3 | P30281 | 11/20 | 0.64 |
| ▸ | JAK3 | P52333 | 6/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.55 |
| ▸ | CDK1 | P06493 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035624 | 0.93 | CDK4 (0.66) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL660218 | 0.92 | CDK4 (0.73) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL15035622 | 0.92 | CDK4 (0.62) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL15035616 | 0.90 | CDK4 (0.60) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL15035620 | 0.90 | CDK4 (0.60) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL15035625 | 0.90 | CDK4 (0.59) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL15035619 | 0.89 | CDK4 (0.58) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL15035626 | 0.89 | CDK4 (0.58) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL10192709 | 0.89 | CDK4 (0.68) | CDK4CCND1CCND2CCND3JAK3 | |
| SCHEMBL10192692 | 0.88 | CDK4 (0.67) | CDK4CCND1CCND2CCND3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | CDK4 1028/4885CCND1 4465/4885CCND2 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.